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INTRODUCTION: Traditionally, implantation of Left Ventricular Assist Devices (LVADs) is performed
via median sternotomy. Recently, less invasive thoracotomy approaches are growing in popularity as
they involve less surgical trauma, potentially less bleeding, and may preserve right ventricular function.
We hypothesized implantation of LVADs via thoracotomy has less perioperative right ventricular failure (RVF) and shorter postoperative length of stay (LOS).
METHODS: Continuous flow LVAD implants from Intermacs between February 6, 2014 - December 31, 2018 were identified. Patients implanted via thoracotomy were propensity matched in a
1:1 ratio with patients implanted via sternotomy. Outcomes were compared between sternotomy
and thoracotomy approach and by device type (axial, centrifugal-flow with hybrid levitation
(CF-HL), centrifugal-flow with full magnetic levitation devices (CF-FML)). The primary outcome was time to first moderate or severe RVF. Secondary outcomes included survival and
LOS.
RESULTS: Overall 978 thoracotomy patients were matched with 978 sternotomy patients. Over the
study period, 242 thoracotomy patients and 219 sternotomy patients developed RVF with no significant difference in time to first moderate to severe RVF by surgical approach overall
(p = 0.27) or within CF-HL (p = 0.36) or CF-FML devices (p = 0.25). Survival did not differ by
implant technique (150 deaths in thoracotomy group, 154 deaths in sternotomy group; p = 0.58).
However, sternotomy approach was associated with a significantly shorter LOS (17 Vs 18 days,
p = 0.009).
CONCLUSION: As compared to sternotomy, implantation of continuous flow LVADs via thoracotomy
approach does not reduce moderate to severe RVF or improve survival but does reduce post-operative
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LOS. Device type did not influence outcomes and most centers did a small volume of thoracotomy
implants.
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While left ventricular assist device (LVAD) therapy has
improved survival and quality of life (QOL) for select
advanced heart failure patients, it remains burdened by significant perioperative complications.1,2 Right ventricular
failure (RVF), in particular, can occur in up to 40% of
implants resulting in increased mortality, poor QOL, and
longer length of stay (LOS).3 Appropriate patient selection
is critical to minimize the risk of RVF, but intraoperative
approaches and strategies are also important factors.4
The traditional surgical approach for LVAD implantation is a full median sternotomy. With decreased device
size in newer generation LVADs, there is growing interest
in less invasive approaches for implantation.5-7 Less invasive approaches typically involve bilateral thoracotomies or
an upper hemi-sternotomy and left thoracotomy. Smaller
series of carefully selected patients demonstrated safety of
the thoracotomy approach and suggested that it may prevent
RVF and reduce LOS.8,9 Thoracotomy approach may also
be a more cost effective approach, some of which is attributable to length of stay.10 Consequently, the FDA has
approved implantation of the HVAD (Medtronic, Minneapolis, MN) and HeartMate 3 (Abbott Laboratories, Abbott
Park, IL) via less invasive thoracotomy approach.
In this study, we aimed to (1) Describe contemporary use
of thoracotomy compared to sternotomy LVAD implantation in “real world” patients as reported to Intermacs, (2)
evaluate the impact of surgical approach on RVF and LOS,

Figure 1

and (3) analyze outcomes by device flow type. We hypothesized that implantation of durable continuous flow LVADs
via thoracotomy approach would result in similar survival,
but less perioperative RVF and a shorter postoperative
LOS, as compared to a median sternotomy.

Methods
We performed a retrospective analysis of the Intermacs Database
supported through the Society of Thoracic Surgeons. The study
was approved by Intermacs Data Collection and Coordinating
Center. The data for this research were provided by The Society
of Thoracic Surgeons’ National Database Access and Publications
Research Program.
Primary durable LVAD implants for patients ≥ 19 years of age
from June 2, 2014 through December 31, 2018 were included as
data on surgical approach only began being collected in Intermacs
on June 2, 2014. Patients with a prior durable LVAD and those
receiving total artificial heart support (TAH), durable biventricular
support (BIVAD), or pulsatile flow LVAD were excluded. To
eliminate any potential influence of outflow location on outcomes,
patients where the LVAD outflow cannula was not anastomosed
to the ascending aorta were also excluded (Figure 1). Once the
cohort of thoracotomy patients was identified, they were propensity matched across all baseline variables in a 1:1 ratio with
patients from the sternotomy group.
Outcomes were compared between groups by surgical
approach (sternotomy vs thoracotomy) and between axial,

Cohort flow diagram of study population.
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centrifugal-flow with hybrid levitation (CF-HL), and centrifugalflow with full magnetic levitation (CF-FML) devices. The primary
outcome was time to first moderate or severe RVF. RVF was
defined according to Intermacs Adverse Events classification version 5.0 (Supplementary Table 1). Moderate to severe RVF
requires elevated right atrial pressure and post-implant utilization
of inotropes for greater than 7 days, inhaled nitric oxide or intravenous vasodilators, or right ventricular assist device support. Secondary outcomes included survival and post-implant LOS. To
evaluate center volume of less invasive implants, the number of
thoracotomy implants done per center in 2016 (midpoint of the
study period) was assessed. The number of temporary or durable
right ventricular assist devices (RVADs) used was also analyzed.
Data were analyzed with SAS version 9.4 (SAS, Cary, NC).
For all statistical testing, we used a 2-sided significance level of
0.05. Outcomes stratified by surgical approach were evaluated in a
propensity score matched cohort with similar pre-implant and
implant characteristics. First, a propensity score was assigned to
each patient using logistic regression for probability of receiving a
thoracotomy based on all variables in supplementary table 2.
Then, propensity score matching was conducted using greedy
nearest neighbor matching with a 0.1 caliper and a 1:1 match ratio.
An appropriate match was found for all 978 thoracotomy patients
(Supplementary Figures 1&2). All variables, even those with p >
0.05 were included in the logistic model. Missing data was
imputed to the group mean and percent missingness was less than
5% in 55 of 75 baseline variables (Supplementary Table 3). For
between-group comparisons, we used a chi-square test for categorical variables. The Kaplan-Meier method with the log-rank test
was used to compare unadjusted all-cause mortality between
patients based on implant approach and pump type.
LOS in the propensity matched cohort was reported using
median and interquartile range and compared using the nonparametric Wilcoxon sign-ranked test. For survival analysis,
patients were censored at transplant, death, cessation of support,
or device exchange.

Results
From an overall available patient cohort of 25,508 implants
in the registry, 11,580 durable continuous flow LVAD
implants met inclusion criteria. Of these, there were 390
patients where the LVAD outflow cannula was anastomosed to a location other than the ascending aorta and 5
patients where surgical approach was a combination of sternotomy and thoracotomy who were also excluded. In total,
11,185 patients remained (Figure 1). Of these, 10,207 were
implanted by traditional sternotomy and 978 implanted
with thoracotomy. Matches were found for all 978 thoracotomy patients for a total of 1956 patients analyzed. The propensity matched cohort was well balanced across all
covariates as observed in all of the standardized means
being substantially <0.1 (Supplementary Table 4). This
included 1512 CF-HL, 230 CF-FML, and 214 axial flow
devices. Of the CF-HL devices, 749 were implanted by sternotomy and 763 by thoracotomy. For the CF-FML devices,
122 were implanted via sternotomy and 108 via thoracotomy. Finally, for axial flow devices there was an even distribution of sternotomy and thoracotomy approaches with
107 patients in each group.
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After propensity matching, pre-implant patient characteristics were compared between sternotomy and thoracotomy groups and mean values are summarized in Table 1.
The groups were well matched with the exception of a statistically significant lower pre-albumin in the thoracotomy
group.
Over the study period, 242 thoracotomy patients and 219
sternotomy patients developed moderate to severe RVF.
This included 29 temporary RVADs, 2 durable RVADs,
and 1 total artificial heart used in the matched sternotomy
group for a total of 34 patients receiving biventricular
mechanical support. In the thoracotomy group, 14 temporary RVADs and 1 durable RVAD were used with 15 total
patients requiring biventricular mechanical support. At 24
months, there was no significant difference across all pump
types in the primary outcome of time to first moderate to
severe RVF by surgical approach (Figure 2). When evaluated by device type, moderate to severe RVF occurred in 54
of the 214 (25.2%) axial flow patients, 35 of 230 (15.2%)
CF-FML patients, and 372 of 1512 (24.6%) CF-HL devices,
which also did not reach statistical significance (Figure 3).
In CF-HL implants, moderate to severe RVF occurred in
195 of 763 (25.6%) patients implanted by thoracotomy
approach and 177 of 749 (23.6%) patients implanted by
sternotomy which was not statistically significant (Figure 4).
For CF-FML devices, 20 of 108 (18.5%) patients implanted
by thoracotomy and 15 of 122 (12.3%) patients implanted
by sternotomy developed moderate to severe RVF which
also did not reach statistical significance (Figure 5). When
compared by surgical approach, there was no difference in
survival over the study period with 150 deaths (15.3%) in
the thoracotomy group and 154 deaths (15.7%) in the sternotomy group (Figure 6).
For patients discharged alive on a device, sternotomy
patients had a median LOS of 18 days (IQR 14-27) compared to 17 days (IQR 13-25) for thoracotomy patients
(p = 0.009). Center volume in 2016 showed 65 centers did
0 thoracotomy implants, 69 centers did 1-5 thoracotomy
implants, with a small number of centers doing more than 5
thoracotomy implants (Table 2).

Discussion
Our investigation of the Intermacs data registry of over
1900 matched continuous flow LVAD implants is the largest evaluation of a thoracotomy approach to LVAD implantation to date. In a propensity matched sample, it
demonstrated that a thoracotomy approach to LVAD placement did not significantly reduce RVF as compared to traditional sternotomy approaches. When compared by device
type, there were also no significant differences in RVF.
With CF-HL and CF-FML devices, which were more commonly implanted by thoracotomy approach, there was no
difference in RVF based on surgical approach. Thoracotomy approach overall was also not associated with any significant difference in survival, but was associated with a
significant reduction in length of stay. In 2016, which was
the midpoint of the study period, most centers did a low
volume of thoracotomy implants with 134 of 164 (82%)
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LVAD Patient Pre-implant Characteristics After Propensity Matching

Pre-implant Characteristics
Age (yrs)
Albumin (g/dl)
Total bilirubin (mg/dl)
Body Mass Index (kg/m2)
BNP (pg/ml)
Body Surface Area (m2)
BUN (mg/dl)
Cholesterol (mg/dl)
Cardiac index (L/min per sq meter)
Creatinine (mg/dl)
Diastolic blood pressure (mmHg)
haemoglobin
Heart Rate
INR (international units)
LDH
LVEDD (cm)
Platelet (K/ul)
Pre-albumin
Pulmonary diastolic pressure (mmHg)
Pulmonary systolic pressure (mmHg)
Pulmonary wedge pressure (mmHg)
Pulmonary vascular resistance (PVR) using cardiac output (wood units)
RA pressure (mmHg)
SGOT/AST (u/l)
SGPT/ALT (u/l)
Sodium (mmol/l)
Systolic blood pressure (mmHg)
WBC (K/ul)
Alcohol Abuse
Aortic Regurg (Moderate/Severe)
Ascites
Blood Type O
Cancer
College
Concommitant surgery
Current Smoker
Drug Abuse
Bridge to Transplant: Listed
Bridge to Transplant: Likely to be listed
Bridge to Transplant: Moderately likely to be listed
Bridge to Transplant: Unlikely to be listed
Destination Therapy
Failure to wean
History of Hepatitis
History of CABG
History of Valve Surgery
ICD
INTERMACS Patient Profile Level 1: Critical Cardiogenic Shock
INTERMACS Patient Profile Level 2: Progressive Decline
INTERMACS Patient Profile Level 3
INTERMACS Patient Profile Level 4
INTERMACS Patient Profile Level 5
INTERMACS Patient Profile Level 6
INTERMACS Patient Profile Level 7
Inotropes
Dialysis
ECMO
IABP

Sternotomy n = 978
54.93
3.60
1.15
27.67
1144.55
2.03
27.36
129.89
2.16
1.33
66.53
11.31
89.87
1.27
366.76
6.84
202.61
20.36
24.93
49.35
23.56
4.18
11.51
44.28
61.64
135.48
104.92
8.26
6.2%
1.0%
4.3%
51.0%
3.8%
56.1%
23.5%
4.5%
8.9%
45.8%
17.1%
8.4%
1.1%
26.3%
1.2%
1.0%
16.5%
5.4%
79.0%
15.7%
31.6%
38.3%
11.9%
1.9%
0.2%
0.3%
81.2%
1.1%
2.1%
11.1%

Thoracotomy n = 978
55.50
3.57
1.18
27.66
1154.16
2.04
26.98
129.03
2.14
1.33
66.16
11.32
89.77
1.28
360.53
6.84
196.41
19.40
24.98
49.35
23.99
4.17
11.66
43.71
57.27
135.34
104.95
8.26
7.3%
1.2%
4.6%
48.5%
4.3%
53.7%
23.2%
4.5%
7.9%
46.3%
17.3%
7.4%
1.4%
26.5%
0.9%
0.8%
16.7%
7.0%
80.8%
14.7%
31.2%
38.8%
12.7%
1.7%
0.5%
0.4%
81.3%
0.9%
1.7%
11.1%

p value
0.31
0.22
0.62
0.96
0.90
0.74
0.58
0.73
0.78
0.88
0.48
0.90
0.91
0.34
0.86
0.92
0.10
0.04
0.90
0.99
0.36
0.95
0.71
0.90
0.65
0.49
0.96
1.00
0.37
0.56
0.77
0.28
0.57
0.35
0.87
1.00
0.41
0.82
0.90
0.40
0.55
0.92
0.51
0.64
0.90
0.16
0.32
0.53
0.85
0.85
0.58
0.74
0.26
0.70
0.96
0.65
0.51
1.00

(continued on next page)
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Table 1 (Continued)
Pre-implant Characteristics

Sternotomy n = 978

Thoracotomy n = 978

Ventilator
LVEF (< 20 severe)
Male
Married
Patient Profile Modifier-Arrythmia
Patient Profile Modifier-Frequent Flyer
Patient Profile Modifier-FF Home
Mitral Regurg (Moderate/Severe)
NYHA = 4
Previous Cardiac Surgeries
Peripheral vascular disease
Race: White
RVEF (severe)
Severe Diabetes
Patient Profile Modifier-TCS
Tricuspid Regurg (Moderate/Severe)
CF-Axial
CF-HL
CF-FML

3.4%
69.5%
76.5%
59.3%
32.2%
18.1%
22.1%
51.5%
81.7%
28.1%
3.1%
67.0%
13.3%
6.7%
31.3%
36.4%
10.9%
78.0%
11.0%

3.6%
69.9%
77.7%
60.4%
30.6%
20.9%
20.1%
50.8%
81.6%
27.5%
3.3%
68.5%
14.1%
7.0%
31.0%
36.7%
10.9%
76.6%
12.5%

doing either 0 or 1-5 and only 8 (5%) performing more than
10.
The first major trial to demonstrate the potential benefit
of a thoracotomy approach in continuous flow LVADs was
the LATERAL trial. In this non-randomized trial, the
implantation of the HVAD (Medtronic) via a thoracotomy
approach in select bridge to transplant patients was safe and
effective when compared to historical sternotomy data.8
For the thoracotomy group in LATERAL, the initial hospital LOS was significantly shorter. The overall incidence of
RVF did not differ with the thoracotomy approach, but the
incidence of moderate RVF decreased dramatically by the

Figure 2

p value
0.81
0.87
0.52
0.60
0.45
0.57
0.52
0.75
0.96
0.76
0.80
0.47
0.67
0.86
0.86
0.89
0.61

first month of follow up and remained low over the study
follow up time. Based on this data, the HVAD received
FDA label expansion for thoracotomy implant in July 2018.
In a single center study, the safety of a less invasive sternalsparing implantation of the HeartMate 3 (Abbott) was also
demonstrated.9 Of 105 consecutive HeartMate 3 implants,
41 were implanted by thoracotomy approach with no intraoperative conversions. The thoracotomy approach patients
had significantly lower incidence of severe RVF, required
fewer blood products, and had a shorter index LOS. The
HeartMate 3 received an FDA indication for less invasive
implantation in January of 2020. Consistent with this

Time to first RVF (Moderate/Severe) on original device by surgical approach.
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Figure 3

Time to first RVF (Moderate/Severe) on original device by device flow type.

timeline, our analysis also revealed that clinical uptake of
thoracotomy implant has been the greatest for the CF-HL
device with 18.3% of implants being done by thoracotomy
across the study period compared to 11% of CF-FML
implants and only 1.8% of implants of axial devices. Since
our study period began several years prior to the FDA
approval of thoracotomy implant for CF-HL and CF-FML
devices, it is likely that the recent experience has an even
greater percentage of thoracotomy implants.

Figure 4

RVF remains an all too common complication after
LVAD placement.11 There have been numerous risk scores
developed using clinical, echocardiographic, and hemodynamic factors to predict RVF.4 However, no single factor or
score has been reliable for patient selection given the complicated interplay of patient characteristics and intraoperative factors that result in RVF. This deficiency in
preventing RVF is a major barrier to more widespread utilization of continuous flow LVADS for the treatment of

Time to first RVF for CF-HL device by surgical approach, sternotomy or thoracotomy.
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Figure 5

Figure 6

987

Time to first RVF for CF-FML device by surgical approach, sternotomy or thoracotomy.

Survival from time of implant to death or last follow up or transplant on original implant device by surgical approach.

Table 2 Distribution of Thoracotomy Implants in 2016 by
Center (centers=164)
# Thoracotomy implants in
2016

Number of centers

Percent

0
1-5
6-10
11+

65
69
22
8

39.63
42.07
13.41
4.88

advanced heart failure. Surgical LVAD implantation by
thoracotomy approach carries several theoretical advantages. Preservation of the pericardium may maintain normal
right ventricular geometry, limit dilation, and preserve normal pressure volume relationship decreasing the incidence
of post-operative RV failure. 12,13 Additionally, in the thoracotomy approach the heart is not manipulated during
inflow anastomosis and by maintaining its normal anatomical position may reduce right ventricular hypoperfusion.
12,14,15
Smaller sternal incisions may reduce the risks of
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bleeding and other complications for future cardiac operations, which is particularly important in bridge to transplant
candidates.
Our analysis of a large, multicenter, “real world” population contradicts prior small reports that suggested less RVF
with the thoracotomy approach. There are several potential
explanations for this discrepancy. To date, none of the prior
studies were randomized. While our analysis was also not
randomized, propensity matching reduces significant differences in baseline characteristics influencing surgical
approach and subsequent outcomes. As demonstrated in
supplementary Table 2, before propensity matching in our
sample there were considerable baseline differences with
patients implanted by thoracotomy approach in general
being “less sick.” This intangible surgical acumen is difficult to account for in retrospective analysis. There is
undoubtedly clinical gestalt that the surgical team takes
into account in evaluating body habitus, trends in central
filling pressures and hemodynamics, trends in renal and
hepatic function as well as assessments of frailty. Balancing
the morbidity of the surgical approach with a need for concomitant procedures (if necessary), pump size, patient body
habitus (small stature or morbid obesity), prior surgical procedures (particularly patent coronary artery bypass grafts),
and frailty/osteopenia are patient variables which need to
be accounted for in determining the optimum surgical
approach for a particular patient.
Moreover, as with any surgical or procedural technique,
outcomes improve with increasing operator experience. For
the majority of our study period, thoracotomy approach
was not FDA approved and the overwhelming majority of
centers did a low volume of the less invasive approach. In
early adopters of new techniques and technologies, there
may be an inherent bias to select patients who may tend
toward a more favorable outcome to ensure early successes
and program adoption. As the volume and surgical experience with thoracotomy approach increase, further investigation into outcomes is warranted. These future evaluations
will be critical to translate the benefits of a less invasive surgical approach to a broader patient profile.
While our propensity matched analysis did not identify a
difference in RVF, we were able to demonstrate a statistically significant shorter post-operative length of stay for
patients with the thoracotomy approach. This reduction in
length of stay is an important factor for a field where cost
and resource utilization remain one barrier to wider utilization and access. However, the absolute decrease in length
of stay for the thoracotomy group was only 1 day making
the clinical relevance of this finding debatable. It will be
important to monitor if the length of stay benefit for thoracotomy approach improves as operators gain more experience with this technique. With the data available, we were
not able analyze the long-term impact of a less invasive surgical approach to LVAD implantation. In particular, thoracotomy approach may have the benefit of improving
outcomes for bridge to transplant patients with shorter LOS
and need for fewer blood products during the subsequent
heart transplant. 16 The less invasive approach may also
improve the transplant operation in terms of less surgical

trauma, perhaps shorter operative length and less bleeding.
Randomized trials comparing surgical approach to LVAD
implantation will be critical to accurately answering these
questions.

Limitations
This analysis has some limitations most of which are associated with large administrative datasets. In this analysis of the
Intermacs registry, we utilized retrospective data, subjecting
the analysis to selection bias, however we attempted to
account for this through propensity matching. Despite propensity matching, the results are only applicable to LVAD
patients eligible for both surgical approaches. Additionally,
not all institutions report to the registry and the data are isolated to the United States practices. Numerous clinically relevant data are not collected in the Intermacs registry, limiting
some of the granularity of the data available for analysis
which could impact the aforementioned selection bias. In
particular, we were unable to assess individual surgeon volume, surgeon experience with thoracotomy approach, pretreatment frailty, or account for institutional practices and
biases on inotropic support or initiation of RV mechanical
support. The basis of our model and comparison consisted of
a predetermined set of variables based on clinical interest.
While data coverage was good for most variables a few had
a large percent missing. We elected to keep this small number of covariates in the propensity score model despite their
messiness and it is unlikely their inclusion significantly
impacted the assigned propensity score for a patient. In our
analysis, we also did not investigate the impact of dependence induced by propensity matching on our treatment
effect. Since the purpose of our analysis was to determine
outcomes based on surgical approach, our propensity matching was completed based on the probability of receiving a
thoracotomy. Surgical approach is closely associated with
device type. Therefore, device type was included as a covariate in the propensity model. This does not guarantee covariate balance by device type and could potentially bias the
device effect estimates. However, in this specific analysis
our comparison groups had similar distributions of device
types. Finally, updated definitions of adverse events, including RVF, for trials and registries of LVAD patients were
recently proposed.17 The Intermacs definition analyzed historically and, in this manuscript, considered RVF a
“condition” based on the need for prolonged inotropes or
RVAD support. The definition of RVF was devised after
concerns were raised about how to translate this “condition”
into “adverse events” in research and regulatory evaluation
of devices. While the updated definition published in 2020 is
recommended going forward, these definitions are only now
being considered for extensive mapping of prior data within
the Intermacs database and it is not feasible to apply to the
data collected during our study period.

Conclusion
In our multi-institutional, propensity matched analysis of
The Society of Thoracic Surgeons’ Intermacs registry
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comparing 1956 patients receiving durable LVAD, we
found that the less-invasive, thoracotomy approach to
implantation did not decrease RVF in short term follow
up, as compared to traditional sternotomy approaches.
While there were unadjusted differences, we did not
identify any difference in RVF between or within pump
types based on surgical approach and no difference in
mortality in the matched sets. Thoracotomy approach
was associated with shorter post-operative LOS. Most
centers performed a low volume of thoracotomy implants
during the study period. Future randomized investigations
of surgical approach are needed to clarify which patients
benefit from the traditional sternotomy and what best
practices are for thoracotomy approaches.
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